Predicting and Addressing Relapse After HCT
Measurable Residual Disease in AML
Release date: March 9, 2023
Overview
This webinar will focus on recent and future research on measurable residual disease (MRD) and precision medicine as methods to predict and reduce relapse risk after allogeneic hematopoietic cell transplant (HCT). While allogeneic HCT is the only curative treatment option for many blood cancers and disorders like acute myeloid leukemia (AML), relapse is often the top reason for treatment failure. While techniques for predicting, monitoring, preventing and treating relapse vary greatly throughout the transplant and hematology/oncology communities, advances in precision medicine, MRD testing and other cellular therapies can provide more standardized approaches.
During this interactive roundtable-style webinar, expert panelists from the Pre-MEASURE and currently enrolling MEASURE (Molecular Evaluation of AML patients after Stem cell transplant to Understand Relapse Events) clinical trials will discuss some of the latest and ongoing research in MRD, precision medicine and emerging cellular therapies that can reduce relapse risk after HCT. Content will be relevant for both transplant centers and community hematologists/oncologists who refer out for transplant and cellular therapies, discussing the role that all practitioners can play in improving patient outcomes.
Interested in claiming CME or CE credit?
Be sure to complete the pre-test here, then complete the post-test after watching the webinar. The post-test link can be found in the on-demand webinar platform in the related resources tab. For more information, see the instructions for participation and requesting credit below.
Target Audience
This educational activity is intended for physicians, nurses and other members of the health care team who care for patients who may benefit from hematopoietic stem cell transplantation.
Learning Objectives
- Review recent trends in genomic testing and allogeneic HCT in AML
- Recognize current and ongoing research in MRD and precision medicine in AML
- Describe novel strategies in cellular therapy to reduce relapse risk for patients with AML
- Discuss the Pre-MEASURE study results and the currently enrolling MEASURE study protocol
- Explain the role transplant centers and community hematology/oncology practices can play in reducing relapse risk and improving outcomes for their AML patients
Faculty
Jeff Auletta, MD
NMDP
CIBMTR® (Center for International Blood and Marrow Transplant Research®)
Nationwide Children's Hospital
Christopher J. Gibson, MD
Dana Farber Cancer Institute
Harvard Medical School
Michael R. Grunwald, MD, FACP
Levine Cancer Institute, Atrium Health
Wake Forest University School of Medicine
Elizabeth Krakow, MD, CM, MS
Fred Hutch Cancer Center
University of Washington
Amandeep Salhotra, MD
City of Hope
Planning Committee
Jeff Auletta, MD
NMDP
CIBMTR
Nationwide Children's Hospital
Anna Cincotta, FNP
Senior Clinical Operations Partner
NMDP
Christopher J. Gibson, MD
Dana Farber Cancer Institute
Harvard Medical School
Michael R. Grunwald, MD, FACP
Levine Cancer Institute, Atrium Health
Wake Forest University School of Medicine
Elizabeth Krakow, MD, CM, MS
Fred Hutch Cancer Center
University of Washington
Amandeep Salhotra, MD
City of Hope
Stephen Spellman, MBS
Vice President of Research and Senior Scientific Director
CIBMTR
NMDP
Instructions for participating and request credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the post-test is required to successfully complete this activity. The participant may take the test until successfully passed.
If you are requesting AMA credits, ANCC credits or a certificate of participation, your certificate will be available for download.
Accredited provider
This activity is jointly provided by The France Foundation and NMDP.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and NMDP. The France Foundation is jointly accredited by the Accreditation Council for Continuing
Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit designation
- Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Nurses: The France Foundation designates this activity for 1.0 contact hour.
- Other healthcare professionals: All other healthcare professionals completing this course will be issued a statement of participation.
Disclosure policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and NMDP require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and NMDP resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and NMDP to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and NMDPare committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
| Name of Individual | Individual's Role in Activity | Name of Commercial Entity | Nature of Relationship(s) | Mechanism(s) Implemented to Resolve Conflict of Interest |
|---|---|---|---|---|
| Amandeep Salhotra, MD | Planning Committee Member, Faculty | 1. Kadmon, Sanofi 2. Sanofi 3. BMS, Kura Oncology |
1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member. Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
| Anna Cincotta, FNP | Planning Committee, Content Reviewer | No relevant financial disclosures | NA | NA |
| Christopher J. Gibson, MD | Planning Committee Member, Faculty | No relevant financial disclosures | NA | NA |
| Elizabeth Krakow, MD, CM, MS | Planning Committee Member, Faculty | 1. Vitalink AI, Institute for Systems Biology 2. HighPass BIO |
1. Advisory Board Member 2. Contract Research (Paid to Fred Hutch) The relationship with HighPass BIO ended in 02/2023. |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member. Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
| Heather Tarbox, MPH | TFF Staff | No relevant financial disclosures | NA | NA |
| Jas Chahal, PhD | TFF Staff | No relevant financial disclosures | NA | NA |
| Jeff Auletta, MD | Planning Committee Member, Moderator | 1. AscellaHealth | 1. Non-CE Consulting |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member. Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
| Karla Dawson, MPH | NMDP Staff | No relevant financial disclosures | NA | NA |
| Kelly Wilson, MSN, RN | NMDP Staff | No relevant financial disclosures | NA | NA |
| Michael R. Grunwald, MD, FACP | Planning Committee Member, Faculty |
|
|
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. |
| Samantha Watters, MPH | NMDP Staff | No relevant financial disclosures | NA | NA |
| Stephen Spellman, MBS | Planning Committee Member | No relevant financial disclosures | NA | NA |
Disclosure of Unlabeled Use
TFF and NMDP require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and NMDP do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
TFF and NMDP present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, NMDP, and the commercial supporter(s) assume no liability for the information herein.
Copyright information
Copyright ©2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
Privacy policy
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at (860) 434-1650 or info@francefoundation.com.
Resources
Exploring a standardized approach to MRD
Evolution of HCT self-paced CME/CE course with lesson on MRD in Part 2: Eligibility for Transplant